Regeneron Pharmaceuticals

Sanofi gibt auf seinem Immunology Investor Event ein Update zu seiner Immunologie-Strategie bekannt

(PRESSEMITTEILUNG) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert…

2 years ago

Sanofi to provide an update on its Immunology strategy at its Immunology Investor Event

(PRESS RELEASE) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced…

2 years ago

Sanofi, Regeneron Pharmaceuticals partner to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology

Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration Companies agree to jointly advance PD-1 and other new immuno-oncology antibodies - Sanofi commits…

9 years ago

Sanofi and Regeneron Pharmaceuticals presented positive results from Sarilumab Phase 3 Rheumatoid Arthritis Trial at European League Against Rheumatism Annual Congress in Paris

Both doses of investigational drug sarilumab met all three co-primary endpoints New data include major clinical response rates and ACR20…

10 years ago

Alirocumab clinical studies to be presented by Sanofi and Regeneron Pharmaceuticals at American College of Cardiology’s 63rd Annual Scientific Session in Washington D.C. March 29-31

Companies To Host Investor Conference Call on Alirocumab on March 31 at 9 a.m. EDT Paris, France and Tarrytown, NY,…